<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04347200</url>
  </required_header>
  <id_info>
    <org_study_id>REGATTA119021970</org_study_id>
    <nct_id>NCT04347200</nct_id>
  </id_info>
  <brief_title>REGistry of Long-term AnTithrombotic TherApy-1</brief_title>
  <acronym>REGATTA-1</acronym>
  <official_title>Registry Dedicated to Assess the Risk of Ischemic and Hemorrhagic Complications of Long-term Antithrombotic Therapy in Patients With Chronic Coronary Syndromes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Medical Research Center for Cardiology, Ministry of Health of Russian Federation</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Medical Research Center for Cardiology, Ministry of Health of Russian Federation</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To assess the rates of ischemic and hemorrhagic complications of long-term antithrombotic
      therapy in patients with chronic coronary syndromes
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The register is a Russian prospective single-center observational study of patients who have
      indications for long-term antithrombotic therapy in connection with chronic coronary
      syndromes
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 15, 2015</start_date>
  <completion_date type="Anticipated">December 31, 2025</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2025</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>5 Years</target_duration>
  <primary_outcome>
    <measure>composite of major adverse cardiovascular events (MACE)</measure>
    <time_frame>inclusion up to 5 years</time_frame>
    <description>stroke, myocardial infarction, stent thrombosis [definite or probable], or urgent revascularization, cardiac death</description>
  </primary_outcome>
  <primary_outcome>
    <measure>composite of any bleeding events</measure>
    <time_frame>inclusion up to 5 years</time_frame>
    <description>major, clinically relevant nonmajor, minor (BARC, ISTH)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Severity of peripheral atherosclerosis</measure>
    <time_frame>inclusion</time_frame>
    <description>Assessment will be performed with the use of duplex scanning</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mutations in following genes</measure>
    <time_frame>inclusion</time_frame>
    <description>CYP2C19*, ABCB1</description>
  </secondary_outcome>
  <enrollment type="Anticipated">2000</enrollment>
  <condition>Coronary Artery Disease (CAD) (E.G., Angina, Myocardial Infarction, and Atherosclerotic Heart Disease (ASHD))</condition>
  <condition>Peripheral Artery Disease</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Antiplatelet Drug</intervention_name>
    <description>single or dual antiplatelets, triple antithrombotic theraphy</description>
    <other_name>anticoagulant Drug</other_name>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      whole blood, serum, white cells, urine
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Hospitalized or outpatients with confirmed chronic coronary syndromes
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  coronary artery disease , confirmed by history of myocardial infarction, or
             revascularization, or definitive evidence of CAD on imaging

        Exclusion Criteria:

          -  Subjects who are unwilling or unable to provide informed consent.

          -  ACS within 12 months before inclusion

          -  Severe CHF (NYHA IV)

          -  Stroke within 6 months before inclusion

          -  Severe liver or muscle disease

          -  Severe kidney disease / renal failure with creatinine &gt; 3 mg/dl

          -  Conceivable impossibility to come in touch with the patient or his family at 1-year
             after the intervention -
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Elizaveta Panchenko, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Medical Research Center for Cardiology, Ministry of Health of Russian Federation</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Andrey Komarov, PhD</last_name>
    <phone>+79161813257</phone>
    <email>andrkomarov@mail.ru</email>
  </overall_contact>
  <location>
    <facility>
      <name>National Medical Research Center for Cardiology, Ministry of Health of Russian Federation</name>
      <address>
        <city>Moscow</city>
        <zip>121552</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Elizaveta Panchenko, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Olga Shakhmatova, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Andrey Komarov, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Elena Yarovaya, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Alla Shuleshova, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Russian Federation</country>
  </location_countries>
  <reference>
    <citation>Eikelboom JW, Connolly SJ, Bosch J, Dagenais GR, Hart RG, Shestakovska O, Diaz R, Alings M, Lonn EM, Anand SS, Widimsky P, Hori M, Avezum A, Piegas LS, Branch KRH, Probstfield J, Bhatt DL, Zhu J, Liang Y, Maggioni AP, Lopez-Jaramillo P, O'Donnell M, Kakkar AK, Fox KAA, Parkhomenko AN, Ertl G, Störk S, Keltai M, Ryden L, Pogosova N, Dans AL, Lanas F, Commerford PJ, Torp-Pedersen C, Guzik TJ, Verhamme PB, Vinereanu D, Kim JH, Tonkin AM, Lewis BS, Felix C, Yusoff K, Steg PG, Metsarinne KP, Cook Bruns N, Misselwitz F, Chen E, Leong D, Yusuf S; COMPASS Investigators. Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease. N Engl J Med. 2017 Oct 5;377(14):1319-1330. doi: 10.1056/NEJMoa1709118. Epub 2017 Aug 27.</citation>
    <PMID>28844192</PMID>
  </reference>
  <reference>
    <citation>Darmon A, Sorbets E, Ducrocq G, Elbez Y, Abtan J, Popovic B, Ohman EM, Röther J, Wilson PF, Montalescot G, Zeymer U, Bhatt DL, Steg PG; REACH Registry Investigators. Association of Multiple Enrichment Criteria With Ischemic and Bleeding Risks Among COMPASS-Eligible Patients. J Am Coll Cardiol. 2019 Jul 2;73(25):3281-3291. doi: 10.1016/j.jacc.2019.04.046.</citation>
    <PMID>31248549</PMID>
  </reference>
  <reference>
    <citation>Komarov A, Panchenko E, Dobrovolsky A, Karpov Y, Deev A, Titaeva E, Davletov K, Eshkeeva A, Markova L. D-dimer and platelet aggregability are related to thrombotic events in patients with peripheral arterial occlusive disease. Eur Heart J. 2002 Aug;23(16):1309-16.</citation>
    <PMID>12175668</PMID>
  </reference>
  <reference>
    <citation>Komarov AL, Shakhmatova OO, Muraseeva VG, Novikova ES, Guskova EV, Panchenko EP. Proton pump inhibitors receiving and prognosis of patients after scheduled percutaneous coronary interventions. Ter Arkh. 2018 Sep 20;90(9):92-100. doi: 10.26442/terarkh201890992-100.</citation>
    <PMID>30701742</PMID>
  </reference>
  <reference>
    <citation>Darmon A, Bhatt DL, Elbez Y, Aboyans V, Anand S, Bosch J, Branch KR, Connolly SJ, Dyal L, Eikelboom JW, Fox KAA, Keltai K, Probstfield J, Yusuf S, Abtan J, Sorbets E, Eagle KA, Ducrocq G, Steg PG. External applicability of the COMPASS trial: an analysis of the reduction of atherothrombosis for continued health (REACH) registry. Eur Heart J. 2018 Mar 1;39(9):750-757a. doi: 10.1093/eurheartj/ehx658.</citation>
    <PMID>29186454</PMID>
  </reference>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>April 10, 2020</study_first_submitted>
  <study_first_submitted_qc>April 14, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 15, 2020</study_first_posted>
  <last_update_submitted>April 14, 2020</last_update_submitted>
  <last_update_submitted_qc>April 14, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 15, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>National Medical Research Center for Cardiology, Ministry of Health of Russian Federation</investigator_affiliation>
    <investigator_full_name>Elizaveta Panchenko</investigator_full_name>
    <investigator_title>professor</investigator_title>
  </responsible_party>
  <keyword>Coronary Artery Disease, Peripheral Artery Disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
    <mesh_term>Heart Diseases</mesh_term>
    <mesh_term>Myocardial Infarction</mesh_term>
    <mesh_term>Peripheral Arterial Disease</mesh_term>
    <mesh_term>Infarction</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anticoagulants</mesh_term>
    <mesh_term>Platelet Aggregation Inhibitors</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Individual participant data that underlie the results reported in the article after deidentification (text, tables, figures)</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_time_frame>Beginning 9 months and ending 36 months following publication</ipd_time_frame>
    <ipd_access_criteria>Researchers who provide a methodologically sound proposal . For individual participant data meta-analysis.</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

